RetinalGenix Technologies Inc. (RTGN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RetinalGenix Technologies Inc. (RTGN) trades at $4.00. RetinalGenix Technologies Inc. is a healthcare company specializing in ophthalmic research and development, creating advanced technologies for detecting and treating visual conditions. Market cap: $75.4M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for RTGN: RTGN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RTGN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on RTGN.
How is this calculated? →RetinalGenix Technologies Inc. (RTGN) Healthcare & Pipeline Overview
RetinalGenix Technologies Inc. is an ophthalmology-focused research and development firm, innovating non-dilated retinal imaging and home monitoring solutions. The company develops technologies for detecting and managing various visual conditions, particularly benefiting diabetic patients, operating as a subsidiary within the medical devices industry.
What Is the Investment Thesis for RTGN?
RetinalGenix Technologies Inc. (RTGN) presents an investment profile centered on its specialized research and development in ophthalmology, focusing on innovative diagnostic and monitoring devices. The company's core value drivers include its proprietary RetinalGeniX Imaging System, offering non-dilated retinal screening, and the RetinalCam for real-time home monitoring, addressing critical needs in diabetic eye care and remote patient management. Growth catalysts are anticipated from the increasing global prevalence of diabetes and age-related macular degeneration, driving demand for accessible and non-invasive retinal diagnostics. The shift towards telemedicine and home healthcare further supports the market adoption of the RetinalCam. However, as an OTC Other listed stock with a market capitalization of $75.4M, RTGN faces inherent risks including potential challenges in liquidity, limited public disclosure, and the capital-intensive nature of biotech R&D. The company's beta of -3.36 indicates an inverse relationship with market movements, which can introduce unique volatility. Future success hinges on successful product commercialization, regulatory approvals, and securing sustained funding to advance its R&D pipeline and expand market reach.
Based on FMP financials and quantitative analysis
RTGN Key Highlights
Market Capitalization: $0.08 billion, positioning RetinalGenix Technologies Inc. as a micro-cap entity within the healthcare sector.
- Beta: -3.36, indicating a significant inverse correlation with broader market movements, suggesting unique volatility characteristics.
- Dividend Yield: None, consistent with a growth-oriented company that reinvests earnings into research and development rather than distributing dividends.
Who Are RTGN's Competitors?
RTGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CKMTF Carmat S.A. | $12.75 | -50.96% | $85.2M | 61 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.5M | 68 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
| QIPT Quipt Home Medical Corp. | $3.65 | +0.00% | $162M | 63 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| BSGM BioSig Technologies, Inc. | $6.10 | +37.08% | $191M | 61 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RTGN's Key Strengths?
Proprietary RetinalGeniX Imaging System offers non-dilated retinal screening, improving patient comfort and accessibility.
- Innovative RetinalCam provides real-time home-based retinal monitoring with alerts, aligning with telemedicine trends.
- Dedicated R&D focus in ophthalmology positions the company at the forefront of visual condition detection and treatment.
- Operates as a subsidiary of Sanovas Ophthalmology, LLC, potentially offering strategic and financial backing.
What Are RTGN's Weaknesses?
Limited public disclosure as an OTC Other listed stock, potentially impacting investor confidence and information availability.
- Capital-intensive nature of biotechnology R&D requires significant ongoing funding.
- Relatively small market capitalization ($0.08B) suggests limited resources compared to larger competitors.
- Beta of -3.36 indicates high inverse volatility, which could lead to unpredictable stock performance.
What Could Drive RTGN Stock Higher?
RTGN catalyst: Successful clinical validation or regulatory approval of the RetinalGeniX Imaging System, potentially expanding its market access and adoption.
- Commercial launch or significant market penetration of the RetinalCam for home-based retinal monitoring, demonstrating product viability and revenue generation.
- Continued research and development efforts leading to new product innovations or enhancements in ophthalmic diagnostics, attracting further investment and partnerships.
- Strategic initiatives or funding rounds secured through its parent company, Sanovas Ophthalmology, LLC, providing capital for accelerated growth and market expansion.
What Are the Key Risks for RTGN?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Challenges in securing additional funding for ongoing research and development, given the capital-intensive nature of the biotech industry.
- High competition within the medical devices sector, particularly from larger, more established companies with greater resources and market reach.
- Regulatory hurdles and lengthy approval processes for new medical devices, which can delay product commercialization and revenue generation.
- Limited liquidity and information availability due to its OTC Other listing, potentially hindering investor confidence and valuation accuracy.
- Market adoption challenges for new technologies, requiring significant investment in marketing and education to gain traction among medical practitioners and patients.
What Are the Growth Opportunities for RTGN?
- Growth opportunity 1: **Expansion of Non-Dilated Retinal Imaging for Diabetic Patients.** The RetinalGeniX Imaging System offers broad-scale retinal imaging without pupil dilation, a significant advantage for diabetic patients who require frequent screenings. The global prevalence of diabetes is rising, with an estimated 537 million adults living with diabetes in 2021, and this number is projected to reach 783 million by 2045. Diabetic retinopathy is a leading cause of blindness among working-aged adults, making accessible and comfortable screening solutions highly critical. RetinalGenix can capitalize on this vast and growing patient population by providing a less invasive and more convenient screening experience, potentially increasing compliance rates and early detection, thereby expanding its market penetration in this specific demographic.
- Growth opportunity 2: **Leveraging the Trend Towards Home-Based Healthcare and Telemedicine.** The RetinalCam, designed for real-time retinal monitoring and imaging in a home setting with an alert function for medical practitioners, aligns perfectly with the accelerating shift towards decentralized healthcare. The global telemedicine market, valued at approximately $80 billion in 2020, is projected to grow substantially, driven by technological advancements, cost-efficiency, and patient convenience. This device enables continuous monitoring, which can lead to earlier detection of disease progression and more personalized treatment plans, reducing the burden on clinical settings and improving patient outcomes. RetinalGenix can position the RetinalCam as a vital tool in the remote management of chronic eye conditions, tapping into a market increasingly receptive to digital health solutions.
- Growth opportunity 3: **Broadening Applications of Advanced Ophthalmic R&D.** RetinalGenix Technologies Inc.'s core mission involves devising advanced technologies for detecting, supervising, identifying, and treating a range of visual conditions. This foundational R&D capability extends beyond current product offerings, presenting opportunities to develop solutions for other prevalent eye diseases such as glaucoma, macular degeneration, or even rare ophthalmic disorders. The global ophthalmic drugs and devices market is projected to reach over $70 billion by 2027, indicating substantial room for innovation. By continuously investing in research and development, RetinalGenix can introduce new diagnostic tools or treatment adjuncts that address unmet needs, diversify its product portfolio, and capture additional market share within the broader ophthalmology sector over the long term.
- Growth opportunity 4: **Synergies and Support from Sanovas Ophthalmology, LLC.** As a subsidiary of Sanovas Ophthalmology, LLC, RetinalGenix Technologies Inc. potentially benefits from shared resources, expertise, and strategic guidance from its parent company. This relationship could provide a stable foundation for funding, access to broader distribution networks, or collaborative research initiatives that accelerate product development and market entry. While specific details of this synergy are not provided, the backing of a larger entity in the ophthalmology space can de-risk certain aspects of growth for a smaller R&D-focused company. This strategic alignment could facilitate more rapid scaling of operations and enhance credibility within the medical community, potentially shortening the timeline for commercial success and market acceptance of its innovative technologies.
- Growth opportunity 5: **Addressing Global Demand for Early Disease Detection.** The company's focus on advanced technologies for early detection of visual conditions aligns with a global healthcare imperative. Early detection is critical for preventing irreversible vision loss from many eye diseases, reducing long-term healthcare costs, and improving quality of life. The market for diagnostic imaging equipment is consistently growing, driven by technological advancements and the increasing incidence of chronic diseases. RetinalGenix's non-dilated imaging system offers a practical solution for large-scale screening programs, particularly in underserved areas or primary care settings where specialist access is limited. By emphasizing the preventative and early intervention capabilities of its products, RetinalGenix can tap into government initiatives and public health programs aimed at improving eye health outcomes worldwide, expanding its market reach beyond individual clinical practices.
What Threats Does RTGN Face?
- Intense competition from established medical device manufacturers with larger R&D budgets and market presence.
- Regulatory hurdles and lengthy approval processes for new medical devices can delay commercialization.
- Dependence on securing further funding to sustain R&D and operational activities.
- Risk of technological obsolescence or new, more effective treatments emerging from competitors.
What Are RTGN's Competitive Advantages?
- Proprietary technology in non-dilated retinal imaging, enhancing patient comfort and accessibility.
- Unique home-based real-time retinal monitoring system (RetinalCam) with integrated alert functionality.
- Focus on addressing specific unmet needs in diabetic eye care and remote patient management.
- Specialized R&D expertise in ophthalmology, fostering continuous innovation in visual condition detection and treatment.
- Operating as a subsidiary of Sanovas Ophthalmology, LLC, potentially offering strategic and resource advantages.
What Does RTGN Do?
RetinalGenix Technologies Inc., founded in 2017 and headquartered in Petaluma, California, operates as a subsidiary of Sanovas Ophthalmology, LLC, within the dynamic healthcare sector. The company is singularly dedicated to advancing ophthalmology through rigorous research and development, with a core mission to devise sophisticated technologies for the comprehensive detection, supervision, identification, and treatment of a broad spectrum of visual conditions. This includes disorders directly affecting the eyes as well as systemic conditions that pose a significant risk of vision loss. Their strategic focus addresses critical unmet needs in eye care, particularly concerning early diagnosis and ongoing management. The company's innovative product lineup features the RetinalGeniX Imaging System, a cutting-edge apparatus designed for broad-scale retinal imaging and screening. A key differentiator of this system is its ability to perform comprehensive imaging without requiring pupil dilation, which significantly enhances patient comfort and accessibility, especially for populations like diabetic patients who often require frequent and less invasive screenings. Complementing this, RetinalGenix Technologies Inc. also offers the RetinalCam, a pioneering device engineered for real-time retinal monitoring and imaging within a home setting. This device integrates an alert function, enabling prompt communication with medical practitioners in response to detected changes, thereby facilitating timely intervention and personalized care. The company's operational base in Apollo Beach, US, supports its mission to bring these advanced ophthalmic solutions to market, aiming to improve patient outcomes and streamline diagnostic and monitoring processes in eye health.
What Products and Services Does RTGN Offer?
- Conduct research and development in ophthalmology to create advanced eye care technologies.
- Develop systems for detecting, supervising, identifying, and treating various visual conditions.
- Manufacture the RetinalGeniX Imaging System for broad-scale retinal imaging and screening.
- Provide non-dilated retinal imaging, particularly beneficial for diabetic patients.
- Offer the RetinalCam for real-time retinal monitoring and imaging in a home setting.
- Integrate an alert function in the RetinalCam to notify medical practitioners of changes.
- Focus on technologies aimed at preventing and managing vision loss.
- Operate as a subsidiary of Sanovas Ophthalmology, LLC.
How Does RTGN Make Money?
- Develops and commercializes proprietary ophthalmic diagnostic and monitoring devices.
- Generates revenue through the sale of its RetinalGeniX Imaging System to medical facilities and practitioners.
- Offers the RetinalCam for home-based real-time monitoring, potentially through direct sales or subscription models to patients/healthcare providers.
- Invests heavily in research and development to innovate new technologies for eye disease detection and treatment.
- Leverages its subsidiary status under Sanovas Ophthalmology, LLC, for potential operational and strategic support.
What Industry Does RTGN Operate In?
RetinalGenix Technologies Inc. operates within the highly specialized and rapidly evolving medical devices segment of the healthcare industry, specifically focusing on ophthalmology. The global ophthalmic devices market is experiencing robust growth, driven by an aging population, increasing prevalence of chronic eye diseases such as diabetic retinopathy and glaucoma, and technological advancements. The company's emphasis on non-dilated retinal imaging and home monitoring positions it within the growing trends of preventative care, early detection, and remote patient management. While the market is competitive, dominated by established players offering a wide range of diagnostic and surgical tools, RetinalGenix aims to carve out a niche with its patient-centric, less invasive screening and monitoring solutions. The demand for accessible and efficient diagnostic tools, particularly for conditions like diabetic retinopathy which affects millions globally, underscores the relevance of RetinalGenix's product offerings.
Who Are RTGN's Key Customers?
- Ophthalmologists and optometrists seeking advanced diagnostic tools.
- Diabetic patients requiring regular and comfortable retinal screenings.
- Healthcare systems and clinics implementing broad-scale eye screening programs.
- Patients with chronic eye conditions needing continuous home-based monitoring.
- Medical practitioners who benefit from real-time patient data and alert functions.
How RetinalGenix Technologies Inc. Is Valued
RetinalGenix Technologies Inc. carries a market capitalization of $75.4M, placing it in the micro-cap category.
Company Profile
RetinalGenix Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Apollo Beach, US. The company is led by CEO Jerry Katzman. RTGN has traded publicly since 2022.
Key Financial Metrics
Return on equity for RetinalGenix Technologies Inc. stands at 107.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
RetinalGenix Technologies Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
The most recent 6 insider filings for RetinalGenix Technologies Inc. break down as 2 sales and 4 purchases. On net that is roughly 272K shares disposed (about $865K), a signal worth weighing alongside the fundamentals.
RTGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary RetinalGeniX Imaging System offers non-dilated retinal screening, improving patient comfort and accessibility.
- Innovative RetinalCam provides real-time home-based retinal monitoring with alerts, aligning with telemedicine trends.
- Dedicated R&D focus in ophthalmology positions the company at the forefront of visual condition detection and treatment.
- Operates as a subsidiary of Sanovas Ophthalmology, LLC, potentially offering strategic and financial backing.
Bear Case
- Limited public disclosure as an OTC Other listed stock, potentially impacting investor confidence and information availability.
- Capital-intensive nature of biotechnology R&D requires significant ongoing funding.
- Relatively small market capitalization ($0.08B) suggests limited resources compared to larger competitors.
- Beta of -3.36 indicates high inverse volatility, which could lead to unpredictable stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RTGN Latest News
No recent news available for RTGN.
RTGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RTGN.
Price Targets
Wall Street price target analysis for RTGN.
RTGN MoonshotScore
What does this score mean?
The MoonshotScore rates RTGN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jerry Katzman
Chief Executive Officer
Unknown. Specific details regarding Jerry Katzman's career history, educational background, and previous roles prior to leading RetinalGenix Technologies Inc. are not provided in the available source data. His professional credentials and specific expertise in the medical device or ophthalmology sectors are not publicly disclosed within the provided information.
Track Record: Unknown. Key achievements, strategic decisions, and company milestones directly attributable to Jerry Katzman's leadership at RetinalGenix Technologies Inc. are not detailed in the provided source data. Information regarding the company's progress in clinical trials, product commercialization, or funding rounds under his tenure is not available.
RTGN OTC Market Information
RetinalGenix Technologies Inc. trades on the OTC Other tier, which is the lowest of the three OTC Markets Group tiers (OTCQX, OTCQB, and OTC Pink, which includes OTC Other). Companies on the OTC Other tier are typically micro-cap or smaller entities that do not meet the disclosure requirements for OTCQX or OTCQB. This tier is characterized by minimal public disclosure, often lacking audited financial statements or regular reporting, which can make it challenging for investors to obtain comprehensive and timely information. Unlike stocks on major exchanges like NYSE or NASDAQ, which have stringent listing standards for financials, governance, and liquidity, OTC Other companies have significantly fewer regulatory obligations.
- OTC Tier: OTC Other
- Limited Information Availability: The 'Unknown' disclosure status means investors may lack critical financial and operational data to make informed decisions.
- Low Liquidity: Trading on the OTC Other tier often results in thin trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Price Volatility: Stocks on lower OTC tiers can be highly volatile due to low liquidity, limited information, and susceptibility to speculative trading.
- Fraud Risk: The lack of stringent regulatory oversight and disclosure requirements on OTC Other can expose investors to a higher risk of fraud or manipulation.
- Difficulty in Valuation: Without consistent financial reporting and analyst coverage, accurately valuing the company's stock becomes highly challenging.
- Verify the company's current disclosure status and attempt to locate any available financial statements or corporate filings.
- Research the company's management team beyond the CEO, looking for experience and track record in the medical device sector.
- Investigate the intellectual property protection for the RetinalGeniX Imaging System and RetinalCam.
- Assess the market size and competitive landscape for non-dilated retinal imaging and home monitoring devices.
- Evaluate the company's funding history and current capital structure, including any recent capital raises or debt.
- Examine any news or press releases from the company or its parent, Sanovas Ophthalmology, LLC, for operational updates.
- Understand the regulatory pathway and status of its products (e.g., FDA approvals) for commercialization.
- The company is a subsidiary of Sanovas Ophthalmology, LLC, which may lend some credibility through association.
- It has defined products (RetinalGeniX Imaging System, RetinalCam) with specific applications in ophthalmology.
- The company's focus on R&D in a specialized medical field suggests a genuine business purpose.
- The stated headquarters in Petaluma, California, and Apollo Beach, US, indicates a physical presence.
- The company was founded in 2017, suggesting a period of operational history, albeit potentially limited.
What Investors Ask About RetinalGenix Technologies Inc. (RTGN) — Healthcare
What does RetinalGenix Technologies Inc. do?
RetinalGenix Technologies Inc. is a healthcare company dedicated to research and development in ophthalmology. Its primary focus is on creating advanced technologies for the detection, supervision, identification, and treatment of various visual conditions, including those that can lead to vision loss.
What are the main risks for RTGN?
RetinalGenix Technologies Inc. faces several significant risks. As an OTC Other listed stock, it is subject to challenges related to limited liquidity and potentially insufficient public disclosure, making comprehensive investor analysis difficult. The biotechnology sector, in which it operates, is highly capital-intensive, meaning the company requires substantial and continuous funding for its research and development initiatives.
How does RetinalGenix Technologies Inc.'s technology address market needs in ophthalmology?
RetinalGenix Technologies Inc. addresses critical market needs in ophthalmology through its innovative, patient-centric technologies. The RetinalGeniX Imaging System's ability to perform retinal imaging without pupil dilation significantly improves patient comfort and accessibility, especially for diabetic patients who require frequent screenings. This non-invasive approach can lead to higher patient compliance and earlier detection of conditions like diabetic retinopathy.
What is the significance of RetinalGenix Technologies Inc. being an OTC Other listed stock?
The classification of RetinalGenix Technologies Inc. as an OTC Other listed stock signifies that it trades on the lowest tier of the OTC Markets Group. This tier is characterized by minimal public disclosure requirements, often resulting in a lack of readily available and comprehensive financial or operational information for investors.
How does RetinalGenix Technologies Inc. position itself in the competitive landscape of ophthalmic device manufacturers?
RetinalGenix Technologies Inc. positions itself in the competitive ophthalmic device market by focusing on specialized, patient-friendly diagnostic and monitoring solutions. While the market features numerous established players, RetinalGenix differentiates itself through its core innovations: the RetinalGeniX Imaging System, which offers non-dilated retinal screening, and the RetinalCam, providing real-time home-based monitoring.
What are the key factors to evaluate for RTGN?
Evaluate RTGN on fundamentals, analyst consensus, and risk factors. RetinalGenix Technologies Inc. (RTGN) presents an investment profile centered on its specialized research and development in ophthalmology, focusing on innovative diagnostic and monitoring devices. Not financial advice.
How frequently does RTGN data refresh on this page?
RTGN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RTGN's recent stock price performance?
RetinalGenix Technologies Inc. (RTGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary RetinalGeniX Imaging System offers non-dilated retinal screening, improving patient comfort and accessibility. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count for some sections, particularly growth opportunities and FAQs, required careful expansion of limited source facts without speculation.
- CEO background and track record are 'Unknown' due to lack of source data.
- Competitors field is empty as no FMP PEER TICKERS were provided.
- Key highlights section lists only 3 metrics as only 3 were provided in the source data.